Sung Ji Nam
Stock Analyst at Scotiabank
(1.98)
# 2,751
Out of 4,818 analysts
73
Total ratings
35.48%
Success rate
-8.39%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $4.10 | -2.44% | 6 | Apr 2, 2025 | |
| MYGN Myriad Genetics | Maintains: Sector Outperform | $24 → $20 | $7.28 | +174.91% | 3 | Apr 1, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.17 | +70.94% | 5 | Mar 25, 2025 | |
| GH Guardant Health | Maintains: Sector Outperform | $47 → $52 | $45.64 | +13.94% | 4 | Feb 24, 2025 | |
| EXAS Exact Sciences | Maintains: Sector Outperform | $70 → $73 | $44.13 | +65.42% | 2 | Feb 24, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Sector Outperform | $10 → $12 | $7.37 | +62.82% | 2 | Feb 13, 2025 | |
| WAT Waters | Upgrades: Sector Outperform | $430 → $450 | $334.86 | +34.38% | 2 | Feb 13, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $88 → $90 | $50.16 | +79.43% | 2 | Feb 6, 2025 | |
| TWST Twist Bioscience | Maintains: Sector Outperform | $54 → $62 | $37.62 | +64.81% | 5 | Feb 4, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Sector Perform | $605 → $650 | $431.64 | +50.59% | 13 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $265 | $196.31 | +34.99% | 1 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $31.47 | +39.84% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $37 → $44 | $21.36 | +106.04% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $17.84 | +96.19% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $3 | $0.49 | +510.50% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $176 → $164 | $76.25 | +115.08% | 9 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $6.43 | -6.69% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $18.95 | - | 3 | Nov 24, 2020 |
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $4.10
Upside: -2.44%
Myriad Genetics
Apr 1, 2025
Maintains: Sector Outperform
Price Target: $24 → $20
Current: $7.28
Upside: +174.91%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.17
Upside: +70.94%
Guardant Health
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $47 → $52
Current: $45.64
Upside: +13.94%
Exact Sciences
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $44.13
Upside: +65.42%
Adaptive Biotechnologies
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $7.37
Upside: +62.82%
Waters
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $334.86
Upside: +34.38%
Bio-Techne
Feb 6, 2025
Maintains: Sector Outperform
Price Target: $88 → $90
Current: $50.16
Upside: +79.43%
Twist Bioscience
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $37.62
Upside: +64.81%
Thermo Fisher Scientific
Feb 3, 2025
Maintains: Sector Perform
Price Target: $605 → $650
Current: $431.64
Upside: +50.59%
Dec 23, 2024
Initiates: Sector Perform
Price Target: $265
Current: $196.31
Upside: +34.99%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $31.47
Upside: +39.84%
Nov 6, 2024
Maintains: Sector Outperform
Price Target: $37 → $44
Current: $21.36
Upside: +106.04%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $17.84
Upside: +96.19%
Sep 16, 2024
Initiates: Sector Outperform
Price Target: $3
Current: $0.49
Upside: +510.50%
Aug 15, 2024
Maintains: Sector Outperform
Price Target: $176 → $164
Current: $76.25
Upside: +115.08%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $6.43
Upside: -6.69%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $18.95
Upside: -